This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Vision-Sciences Appoints Cheryl Pegus, MD, MPH To Board Of Directors

Stocks in this article: VSCI

ORANGEBURG, N.Y., March 12, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced that Dr. Cheryl Pegus, a renowned cardiologist and physician executive, has been appointed to the company's board of directors, effectively immediately.

Dr. Pegus has more than 24 years of clinical practice and medical management experience. She currently is a Director of Glytec, LLC, a glycemic clinical software organization in the forefront of in-patient diabetes management. She is also a Strategic Advisor to HealthFleet, Inc., an online interactive prevention company. Previously, she was Chief Medical Officer for Walgreens, responsible for Clinical Affairs, Clinical Quality, Outcomes and Analytics, Employee Health and Wellness, and Clinical Sales. From 2007-2010, she served as the General Manager and founding Chief Medical Officer for SymCare Personalized Health Solutions, a start-up company of Johnson & Johnson. She also held positions of increasing responsibility at Aetna, including the Head of Clinical Products for the Medical Products Business Unit, Inc. and early in her career, served as Medical Director for the Cardiovascular Risk Factors Group at Pfizer.

"We are pleased to welcome Dr. Pegus to the board," said Lewis C. Pell, Chairman of the Vision-Sciences, Inc. board.  "Her significant accomplishments and demonstrated track record of launching healthcare products will provide invaluable insight as we seek to execute our strategy of growth and expansion for our innovative EndoSheath technology."  

"Dr. Pegus's impressive medical management skills have deservedly earned her recognition as an outstanding, results-driven leader," added Cynthia Ansari, President and Chief Executive Officer. "Her practical experience developing successful relationships to expand market share complements our strategy to drive awareness of our EndoSheath platform."

Commenting on her appointment, Dr. Pegus said, "I am delighted to join the Vision-Sciences board and look forward to working with this experienced team. The ease of use, safety and quality of the EndoSheath technology allows clinicians to provide a cost-effective, accessible solution to multiple populations. I hope to utilize my expertise and work with management to advance the evidence base for this relevant technology."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs